Navigation Links
Valeant Pharmaceuticals to Announce 2011 First Quarter Results on May 9, 2011
Date:4/29/2011

MISSISSAUGA, Ontario, April 29, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will host a conference call and a live Internet webcast along with a slide presentation on Monday, May 9, 2011 at 10:00 a.m. ET (7:00 a.m. PT) to discuss results for the 2011 first quarter.

The dial-in number to participate on this call is (877) 295-5743, confirmation code 63195016.  International callers should dial (973) 200-3961, confirmation code 63195016. A replay will be available approximately two hours following the conclusion of the conference call to Monday, May 16, 2011, and can be accessed by dialing (800) 642-1687 or (706) 645-9291, confirmation code 63195016.

The webcast and slide presentation will be hosted in the investor relations section of its corporate Web site at www.valeant.com. Participants should allow approximately five to 10 minutes prior to the call's start time to visit the site and to download any streaming media software needed to listen to the Internet webcast. An online archive of the webcast will be available following the end of the live call in the webcast archive portion of the investor relations section at www.valeant.com.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant can be found at www.valeant.com.

(Logo:  http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Responds to Cephalon Boards Letter
2. Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013
3. Regulatory Update - GSK and Valeant Respond to FDA on ezogabine
4. Valeant Pharmaceuticals Adds Corporate Governance Expert Abe Friedman to its Slate of Proposed Cephalon Directors
5. Valeant Pharmaceuticals Files Presentation for Cephalon Stockholders
6. Valeant Pharmaceuticals Files Preliminary Consent Solicitation Statement With the SEC
7. Promius Pharma and Valeant Form Collaboration to Market Cloderm® Cream in the United States
8. Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash
9. GSK and Valeant Receive European Authorisation for Trobalt (retigabine)
10. Valeant Pharmaceuticals Extends Contract with J. Michael Pearson as CEO and Appoints Him as Chairman of the Board
11. Valeant Pharmaceuticals Completes Acquisition of PharmaSwiss S.A.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... DUBLIN, Ohio , Feb. 4, 2016 ... Pricing Program, or those already participating in the program, ... Guidance, often referred to as the , Mega-Guidance , ... the final guidance is published in September 2016. ... 340B Product and Service Marketing , summarizes the Mega-Guidance,s ...
(Date:2/4/2016)... Feb. 4, 2016 Worldwide Radiology Oncology ... growth as next generation systems provide a way ... for cancer surgery. New systems pinpoint the delivery ... has been such a problem previously, limiting the ... robots take cancer surgery far beyond what has ...
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
Breaking Medicine Technology:
(Date:2/5/2016)... , ... February 05, 2016 , ... ... the addition of micro-needling services in their Napa Valley office. The technique utilizes ... Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part of only a ...
(Date:2/5/2016)... ... ... After years as an active staff surgeon and having served as the ... Carman transitioned to chief of the Division of Plastic Surgery at what is now ... and began a second three-year term in January of 2016. , The original selection ...
(Date:2/5/2016)... ... February 05, 2016 , ... In the fourth quarter of ... at the La Valencia Hotel in San Diego, California to discuss changes in ... year’s most outstanding franchise, walking away with the coveted David Wright Award of ...
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure ... to search for and donate to Give To Cure’s campaign that is crowdfunding clinical ... lets users make and share payments through a smart device. In 2015 alone, Venmo ...
(Date:2/5/2016)... New York, New York (PRWEB) , ... February 05, 2016 , ... ... (APDA) announced the election of Patrick McDermott as Chairman of the National Board of ... welcome Pat as Chairman of the Board,” stated Leslie A. Chambers , APDA ...
Breaking Medicine News(10 mins):